MAIA
MAIA Biotechnology, Inc.
$1.30
0.00%
$79.0M
No data for this timeframe.
Vol
Market Cap$79.0M
Cap SizeMicro Cap
Inst. Holders13 funds
Inst. Value$7.1M
Inst. Activity2 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$203.8K
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases4
Recent Activity
Jun 10, 2026
other
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
<p align="center"><b><i>Additional data from MAIA’s THIO-101 expansion may further support an accele
Jun 3, 2026
Press
MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expansion of its Phase 2
Impact 6/10
Jun 2, 2026
SEC
Two insiders at MAIA Biotechnology purchased $103K in open-market shares, representing 0.13% of market cap. While cluste
CLUSTER — Impact 5/10
Jun 1, 2026
Insider
Gryaznov Sergei bought 2,000 shares
Chief Scientific Officer @ $1.35 ($2.7K)
Jun 1, 2026
Insider
Smith Stan bought 75,000 shares
Director @ $1.34 ($100.2K)
Jun 1, 2026
Insider
Vitoc Vlad bought 72,700 shares
Chief Executive Officer @ $1.39 ($100.9K)
May 19, 2026
SEC
MAIA filed a DEFA14A amending its proxy statement to disclose related-party compensation paid to Radu Vitoc, brother of
DEFA14A — Impact 2/10
May 14, 2026
SEC
MAIA Biotechnology terminated its at-the-market (ATM) offering agreement with H.C. Wainwright & Co., effective seven bus
8-K — Impact 5/10
Price Targets
Historical data — last covering-analyst action Feb 2023. No current recommendation available.
$12.14 (Feb 2023)
Current $1.30
Low $10.27
Median $12.14
High $14.00
2 analysts
$10.27
$14.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▲ +50.0% | $-0.11 — $-0.11 | 34% YoY | 1 |
| Next Q | $-0.12 ▲ +25.0% | $-0.12 — $-0.12 | 56% YoY | 1 |
| Current FY | $-0.52 ▲ +24.6% | $-0.52 — $-0.52 | 29% YoY | 1 |
| Next FY | $1.12 ▼ -58.5% | $-0.46 — $2.70 | 315% YoY | 2 |
Latest Reports
BULLISH
Press
6/10
MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expansion of its Phase 2
Jun 3, 2026
BULLISH
CLUSTER
5/10
Two insiders at MAIA Biotechnology purchased $103K in open-market shares, representing 0.13% of market cap. While cluste
Jun 2, 2026
NEUTRAL
DEFA14A
2/10
MAIA filed a DEFA14A amending its proxy statement to disclose related-party compensation paid to Radu Vitoc, brother of
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| Alyeska Investment Group, L.P. | $3.5M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.9M | — |
| VANGUARD FIDUCIARY TRUST CO | $279.0K | — |
| STATE STREET CORP | $194.5K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Gryaznov Sergei | BUY | $2.7K |
| Jun 1, 2026 | Smith Stan | BUY | $100.2K |
| Jun 1, 2026 | Vitoc Vlad | BUY | $100.9K |
| May 29, 2026 | Himmelreich Jeffrey | A | $0.00 |
| May 29, 2026 | Gryaznov Sergei | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
13 institutional holders with $7.1M total value (5,100,938 shares) as of 2026-Q1. Top holders: ROYAL, Alyeska, VANGUARD. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 268 | $0.00 | 0.0% | — |
| 2 | Alyeska Investment Group, L.P. | 2,500,000 | $3.5M | 49.0% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,074,045 | $2.9M | 40.7% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 199,314 | $279.0K | 3.9% | — |
| 5 | STATE STREET CORP | 138,950 | $194.5K | 2.7% | ADD +83.9% |
| 6 | BlackRock, Inc. | 127,978 | $179.2K | 2.5% | — |
| 7 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 20,071 | $28.1K | 0.4% | — |
| 8 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 14,800 | $19.7K | 0.3% | — |
| 9 | MORGAN STANLEY | 13,859 | $19.4K | 0.3% | DOUBLED +1285.9% |
| 10 | Vanguard Global Advisers, LLC | 11,401 | $16.0K | 0.2% | — |
| 11 | JONES FINANCIAL COMPANIES LLLP | 228 | $299.00 | 0.0% | — |
| 12 | CITIGROUP INC | 22 | $31.00 | 0.0% | — |
| 13 | FMR LLC | 2 | $2.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 75,550 | 138,950 | +83.9% | $194.5K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 1,000 | 13,859 | +1285.9% | $19.4K | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 16,165 | 110,467 | +583.4% | $170.1K | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 5,095 | 832 | -83.7% | $1.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 231 | 29 | -87.4% | $45.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 650,256 | 1,140,769 | +75.4% | $2.1M | 2025-Q2 |
| STATE STREET CORP | ADD | 53,250 | 75,550 | +41.9% | $136.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 300 | 2,120 | +606.7% | $3.8K | 2025-Q2 |
| STATE STREET CORP | ADD | 34,400 | 53,250 | +54.8% | $105.4K | 2024-Q4 |
9 unique insiders with 15 transactions. Net insider value: $203.8K ($203.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Gryaznov Sergei | Chief Scientific Officer | BUY | 2,000 | $1.35 | $2.7K |
| Jun 1, 2026 | Smith Stan | Director | BUY | 75,000 | $1.34 | $100.2K |
| Jun 1, 2026 | Vitoc Vlad | Chief Executive Officer | BUY | 72,700 | $1.39 | $100.9K |
| May 29, 2026 | Himmelreich Jeffrey C | Head of Finance | AWARD | 60,000 | — | — |
| May 29, 2026 | Gryaznov Sergei | Chief Scientific Officer | AWARD | 400,000 | — | — |
| May 29, 2026 | Vitoc Vlad | Chief Executive Officer | AWARD | 800,000 | — | — |
| Apr 10, 2026 | Himmelreich Jeffrey C | Head of Finance | AWARD | 30,000 | — | — |
| Apr 10, 2026 | Gryaznov Sergei | Chief Scientific Officer | AWARD | 400,000 | — | — |
| Apr 10, 2026 | Vitoc Vlad | Chief Executive Officer | AWARD | 800,000 | — | — |
| Mar 31, 2026 | Smith Stan | Director | AWARD | 33,099 | — | — |
| Mar 31, 2026 | Theagene Jean-Manasse | Director | AWARD | 27,258 | — | — |
| Mar 31, 2026 | Luput Cristian | Director | AWARD | 28,556 | — | — |
| Mar 31, 2026 | Louie Ngar Yee | Director | AWARD | 33,748 | — | — |
| Mar 31, 2026 | Guerrero Ramiro | Director | AWARD | 27,258 | — | — |
| Mar 31, 2026 | CHAOUKI STEVEN M | Director | AWARD | 27,907 | — | — |
7 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.4/10.
BULLISH
CLUSTER
5/10
Two insiders at MAIA Biotechnology purchased $103K in open-market shares, representing 0.13% of mark
Jun 2, 2026
NEUTRAL
DEFA14A
2/10
MAIA filed a DEFA14A amending its proxy statement to disclose related-party compensation paid to Rad
May 19, 2026
MIXED
8-K
5/10
MAIA Biotechnology terminated its at-the-market (ATM) offering agreement with H.C. Wainwright & Co.,
May 14, 2026
NEUTRAL
DEFA14A
2/10
MAIA Biotechnology filed an amendment to its definitive proxy statement to include previously omitte
Apr 27, 2026
BULLISH
8-K
7/10
MAIA Biotechnology announced the activation of its first U.S. clinical site for the Phase 2 THIO-101
Apr 16, 2026
BULLISH
8-K
7/10
MAIA Biotechnology announced that its recent $33 million capital raise is expected to fully fund the
Apr 8, 2026
NEUTRAL
DEFA14A
3/10
MAIA Biotechnology filed a definitive proxy statement (DEFA14A) following a recent 8-K filing that r
Apr 7, 2026
BULLISH
6/10
MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expan
Jun 3, 2026
NEUTRAL
5/10
MAIA Biotechnology closed an underwritten public offering of 20 million shares at $1.50 per share, r
Mar 4, 2026
BEARISH
6/10
MAIA Biotechnology announced the pricing of a $30 million underwritten public offering of 20 million
Mar 3, 2026
BEARISH
6/10
MAIA Biotechnology has announced an underwritten public offering of common stock and pre-funded warr
Mar 2, 2026
Historical analyst distribution (last covering-analyst action Feb 2023): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2023. No current recommendation available.
$12.14 mean target (Feb 2023)
$10.27 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $1.30 |
| Target Low | $10.27 |
| Target Mean | $12.14 |
| Target Median | $12.14 |
| Target High | $14.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.11 | $-0.11 | 34.5% | +50.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.12 | $-0.12 | $-0.12 | 55.6% | +25.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.52 | $-0.52 | $-0.52 | 29.2% | +24.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$1.12 | $-0.46 | $2.70 | 315.4% | -58.5% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.110 | |
| 7d ago | $-0.220 | +0.110 |
| 30d ago | $-0.220 | +0.110 |
| 60d ago | $-0.220 | +0.110 |
| 90d ago | $-0.220 | +0.110 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 3, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 10, 2026
other
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
<p align="center"><b><i>Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA</i></b></p>
Jun 4, 2026
other
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
<p align="center"><em><strong>MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cance
Jun 3, 2026
fda
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
<p align="center"><b><i>Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA</i>
Jun 2, 2026
other
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
<p align="justify">CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta
Jun 2, 2026
short_volume
Short Volume: MAIA — 62.8% short (1.2M / 1.9M)
Short: 1,168,568 | Exempt: 5,100 | TRF Vol: 1,860,126 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
MAIA Q1 2026 Earnings Scheduled — 2026-05-07
Apr 29, 2026
short_volume
Short Volume: MAIA — 64.3% short (0.4M / 0.7M)
Short: 440,375 | Exempt: 12 | TRF Vol: 684,422 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
other
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
<p align="center"><b><i>Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survi
Apr 16, 2026
short_volume
Short Volume: MAIA — 62.2% short (0.4M / 0.6M)
Short: 354,961 | Exempt: 0 | TRF Vol: 570,347 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: MAIA — 63.7% short (0.4M / 0.6M)
Short: 388,316 | Exempt: 0 | TRF Vol: 609,819 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
other
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
<p align="center"><b><i>Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentu
Mar 31, 2026
other
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
<p align="center"><b><i>Potential breakthrough therapeutic targets $50B+ global immunotherapy market</i></b><sup><b><i>1</i></b></sup></p>
Mar 27, 2026
short_volume
Short Volume: MAIA — 55.4% short (0.7M / 1.3M)
Short: 729,053 | Exempt: 220 | TRF Vol: 1,315,932 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_volume
Short Volume: MAIA — 66.4% short (0.5M / 0.7M)
Short: 496,632 | Exempt: 0 | TRF Vol: 747,530 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
earnings_calendar
MAIA Q4 2025 Earnings After Market Close — 2026-03-19